Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence

被引:172
作者
Morgan, Todd M. [1 ]
Lange, Paul H. [1 ]
Porter, Michael P. [1 ,2 ]
Lin, Daniel W. [1 ,2 ]
Ellis, William J. [1 ]
Gallaher, Ian S. [1 ]
Vessella, Robert L. [1 ,2 ]
机构
[1] Univ Washington, Dept Urol, Sch Med, Seattle, WA 98195 USA
[2] Puget Sound VA Hlth Care Syst, Seattle, WA USA
关键词
POLYMERASE-CHAIN-REACTION; BONE-MARROW MICROMETASTASIS; OCCULT METASTATIC CELLS; BREAST-CANCER; PERIPHERAL-BLOOD; EPITHELIAL-CELLS; PROGNOSTIC VALUE; MEMBRANE ANTIGEN; POSITIVE CELLS; PROGRESSION;
D O I
10.1158/1078-0432.CCR-08-1754
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Men with apparently localized prostate cancer often relapse years after radical prostatectomy. We sought to determine if epithelial-like cells identified from bone marrow in patients after radical prostatectomy, commonly called disseminated tumor cells (DTC), were associated with biochemical recurrence. Experimental Design: We obtained bone marrow aspirates from 569 men prior to radical prostatectomy and from 34 healthy men with prostate-specific antigens <2.5 ng/mL to establish a comparison group. Additionally, an analytic cohort consisting of 98 patients with no evidence of disease (NED) after radical prostatectomy was established to evaluate the relationship between DTC and biochemical recurrence. Epithelial cells in the bone marrow were detected by magnetic bead enrichment with antibodies to CD45 and CD61 (negative selection) followed by antibodies to human epithelial antigen (positive selection) and confirmation with FITC-labeled anti-BerEP4 antibody. Results: DTC were present in 72% (408 of 569) of patients prior to radical prostatectomy. There was no correlation with pathologic stage, Gleason grade, or preoperative prostate-specific antigens. Three of 34 controls (8.8%) had DTC present. In patients with NED after radical prostatectomy, DTC were present in 56 of 98 (57%). DTC were detected in 12 of 14 (86%) NED patients after radical prostatectomy who subsequently suffered biochemical recurrence. The presence of DTC in NED patients was an independent predictor of recurrence (hazard ratio 6.9; 95% confidence interval, 1.03-45.9). Conclusions: Approximately 70% of men undergoing radical prostatectomy had DTC detected in their bone marrow prior to surgery, suggesting that these cells escape early in the disease. Although preoperative DTC status does not correlate with pathologic risk factors, persistence of DTC after radical prostatectomy in NED patients was an independent predictor of recurrence.
引用
收藏
页码:677 / 683
页数:7
相关论文
共 37 条
[1]   Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J].
Allard, WJ ;
Matera, J ;
Miller, MC ;
Repollet, M ;
Connelly, MC ;
Rao, C ;
Tibbe, AGJ ;
Uhr, JW ;
Terstappen, LWMM .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :6897-6904
[2]   Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? [J].
Amling, CL ;
Bergstralh, EJ ;
Blute, ML ;
Slezak, JM ;
Zincke, H .
JOURNAL OF UROLOGY, 2001, 165 (04) :1146-1151
[3]   Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued rise of biochemical failure after 5 years [J].
Amling, CL ;
Blute, ML ;
Bergstralh, EJ ;
Seay, TM ;
Slezak, J ;
Zincke, H .
JOURNAL OF UROLOGY, 2000, 164 (01) :101-105
[4]   Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy [J].
Berg, Arne ;
Berner, Aasmund ;
Lilleby, Wolfgang ;
Bruland, Oyvind S. ;
Fossa, Sophie D. ;
Nesland, Jahn M. ;
Kvalheim, Gunnar .
INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (08) :1603-1609
[5]   Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer [J].
Bianco, FJ ;
Wood, DP ;
de Oliveira, JG ;
Nemeth, JA ;
Beaman, AA ;
Cher, ML .
PROSTATE, 2001, 49 (04) :235-242
[6]  
Brandt B, 1996, CANCER RES, V56, P4556
[7]  
Braun S, 2001, CANCER RES, V61, P1890
[8]   A pooled analysis of bone marrow micrometastasis in breast cancer [J].
Braun, S ;
Vogl, FD ;
Naume, B ;
Janni, W ;
Osborne, MP ;
Coombes, RC ;
Schlimok, G ;
Diel, IJ ;
Gerber, B ;
Gebauer, G ;
Pierga, JY ;
Marth, C ;
Oruzio, D ;
Wiedswang, G ;
Solomayer, EF ;
Kundt, G ;
Strobl, B ;
Fehm, T ;
Wong, GYC ;
Bliss, J ;
Vincent-Salomon, A ;
Pantel, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) :793-802
[9]   Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J].
Cristofanilli, M ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Matera, J ;
Miller, MC ;
Reuben, JM ;
Doyle, GV ;
Allard, WJ ;
Terstappen, LWMM ;
Hayes, DF .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) :781-791
[10]   IDIOTYPIC VACCINATION AGAINST B-CELL LYMPHOMA LEADS TO DORMANT TUMOR [J].
DYKE, RJ ;
MCBRIDE, H ;
GEORGE, AJT ;
HAMBLIN, TJ ;
STEVENSON, FK .
CELLULAR IMMUNOLOGY, 1991, 132 (01) :70-83